scholarly journals Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India

2017 ◽  
Vol 15 (1) ◽  
pp. 97 ◽  
Author(s):  
Parnita Harsh ◽  
Vipin Gupta ◽  
Saurabh Kedia ◽  
Sawan Bopanna ◽  
Sucharita Pilli ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Bowel Disease ◽  
Viral Infections ◽  
North India ◽  
Inflammatory Bowel ◽  
Human Immunodeficiency Viral

scholarly journals Hepatitis B and C viral infections screening in a Tunisian IBD population under immunosuppressive therapies

2020 ◽  
Vol 40 (3) ◽  
pp. 246
Author(s):  
Mériam Sabbah ◽  
Haythem Yacoub ◽  
Nawel Bellil ◽  
Dorra Trad ◽  
Asma Ouakaa ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Bowel Disease ◽  
Viral Infections ◽  
Viral Reactivation ◽  
Acute Hepatitis C ◽  
Hepatitis C Infection ◽  
Inflammatory Bowel ◽  
Hbs Ag

Background: Immunosuppressive drugs have become a mainstay of therapy for the inflammatory bowel diseases (IBD). Thesetreatments expose to a risk of hepatitis B and C reactivation. Objective: The aim of this study was to assess the prevalence of hepatitis B and C viruses in Tunisian IBD patients on immunosuppressive treatments. Materials and methods: Patients with inflammatory bowel disease were consecutively recruited over a 2 years period (2017-2018). Prevalence of viral hepatitis B and C as well as clinical, biological and virological presentation, management and outcome were assessed. Factors associated to hepatitis B and C were also analyzed (SPSS software, p value <0.05). Results: Seventy four patients with IBD were included: 38women and 36 men. Among them 62 (83.8%) had CD and (16.2%) had UC. Mean age was 43.5±14.2 years. Six patients (8.1%) had at least one positive HVB marker. Hepatitis C infection was found in 4% patients. HBs Ag was positive in only one patient (1.3%) with positive HBV DNA. Anti HBc and anti HBs antibodies were positive respectively in 6 and 4 patients. Vaccination against hepatitis B was proposed for 22% of our patients with negative anti HBc antibodies and HBs Ag. Two patients presented non-severe acute hepatitis C with sustained virological response after antiviral treatment. IBD did not relapse under antiviraltreatment. A 3rd patient had chronic hepatitis C infection. She was treated with Pegylated Interferon alpha and Ribavirine. No cases of viral reactivation have been reported. Noassociated factors to hepatitis B and C viral infections were identified in our study. Conclusion: The prevalence of hepatitis B infection in IBD patients under immunosuppressive therapy was similar to the general population, while the hepatitis C prevalence was higher than the national prevalence. Screening for hepatitis B and Cviral infections is mandatory in inflammatory bowel disease patients. Vaccination against hepatitis B is highly recommended.

Chronic viral hepatitis and inflammatory bowel disease

2021 ◽  
Vol 11 (2) ◽  
pp. 29-34
Author(s):  
G.V. Volynets ◽  
◽  
A.I. Khavkin ◽  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Immunosuppressive Therapy ◽  
Chronic Hepatitis C ◽  
Bowel Disease ◽  
Chronic Viral Hepatitis ◽  
Inflammatory Bowel

The article presents the results of a literature review devoted to the study of the problems of the combined course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), and chronic viral hepatitis (CVH) – chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The frequency of occurrence of CHB and CHC in IBD in different countries is presented, which ranges from 1 to 9%. The clinical course of these combined diseases, the possibility of reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) during immunosuppressive therapy are described. Recommendations on the specifics of examination and management of patients with combined pathology of IBD and CVH are presented. Conclusion. The combined pathology of IBD and CVH is a significant public health problem around the world that requires further large-scale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should be individualized. Key words: inflammatory bowel disease, chronic hepatitis B, chronic hepatitis C, immunosuppressive therapy

scholarly journals The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic

2021 ◽  
Vol 14 ◽  
pp. 175628482098819
Author(s):  
Klaudia Farkas ◽  
Daniella Pigniczki ◽  
Mariann Rutka ◽  
Kata Judit Szántó ◽  
Tamás Resál ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Patient Management ◽  
Clinical Decision Making ◽  
Viral Infections ◽  
Clinical Decision ◽  
The Past ◽  
Rapid Changes ◽  
Inflammatory Bowel ◽  
Practical Recommendations

The coronavirus disease 2019 (COVID-19) outbreak emerged in December 2019 in China and rapidly spread worldwide. Inflammatory bowel disease (IBD) patients are likely to be more susceptible to viral infections, and this is significantly influenced by the type of therapy they receive. Thus, issues specifically concerning the medical treatment of IBD patients were shortly addressed at the beginning of the pandemic. However, recently available data on the occurrence and outcome of SARS-CoV-2 infection in IBD patients does not address the concerns raised at the beginning of the pandemic. Growing evidence and the rapid changes happening over the past few weeks have helped elucidate the current situation, contribute to our understanding of the disease, and many previously raised questions could now be answered. We hereby summarise available evidence regarding viral infections and IBD, focusing on SARS-CoV infections, and we provide practical recommendations related to patient management during the COVID-19 pandemic era.

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Gut ◽  
2010 ◽  
Vol 59 (10) ◽  
pp. 1340-1346 ◽  
Author(s):  
C. Loras ◽  
J. P. Gisbert ◽  
M. Minguez ◽  
O. Merino ◽  
L. Bujanda ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis B ◽  
Immunosuppressive Therapy ◽  
Liver Dysfunction ◽  
Bowel Disease ◽  
Inflammatory Bowel

Sa1124 A Report on the Prevalence and Reactivation Rate of Hepatitis B Virus in Patients With Inflammatory Bowel Disease in Japan

2014 ◽  
Vol 146 (5) ◽  
pp. S-206
Author(s):  
Yoko Yokoyama ◽  
Mikio Kawai ◽  
Koji Kamikozuru ◽  
Masaki Iimuro ◽  
Nobuyuki Hida ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Bowel Disease ◽  
B Virus ◽  
Inflammatory Bowel

scholarly journals Hepatitis B Virus Reactivation Induced by Infliximab Administration in a Patient with Crohn’s Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Yuka Miyake ◽  
Aki Hasebe ◽  
Tetsuya Tanihira ◽  
Akiko Shiraishi ◽  
Yusuke Imai ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Hepatitis B Virus ◽  
Crohn's Disease ◽  
Hepatitis B ◽  
Bowel Disease ◽  
Hbv Dna ◽  
Hbv Reactivation ◽  
B Virus ◽  
Inflammatory Bowel

A 47-year-old man diagnosed with Crohn’s disease was treated with infliximab. He tested negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) but positive for anti-HB core antibody (anti-HBc). He tested positive for hepatitis B virus (HBV-) DNA 3 months after treatment and was administered entecavir. HBV-DNA test showed negative results 1 month later. ALT was persistently within the normal range, and HBV-DNA was persistently negative thereafter despite the continuation of infliximab every 8 weeks. In our hospital, 14 patients with inflammatory bowel disease, who tested negative for HBsAg, were treated with infliximab; 2 of them tested positive for anti-HBs and/or anti-HBc, and HBV reactivation was observed in 1 patient (the present patient). The present case and these findings highlight that careful follow-up is needed in patients with inflammatory bowel disease treated with infliximab who test positive for anti-HBc and/or anti-HBs.

scholarly journals P803 Non-immunity against hepatitis B virus in patients with newly diagnosed inflammatory bowel disease

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S518-S518
Author(s):  
H S Lee ◽  
S J Yeo ◽  
E S Kim ◽  
B I Jang ◽  
Y J Lee ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Bowel Disease ◽  
Newly Diagnosed ◽  
B Virus ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document